InsidersTradesSigma
Follow the Context Therapeutics Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Context Therapeutics Inc. has recorded 21 insider filings. Market capitalisation: €55.1m. The latest transaction was disclosed on 10 June 2025 (Acquisition). Among the most active insiders: Lehr Martin A.. The full history is openly available.
21
Insider Decl.
n/a
Thresholds
€319,619
18 ops.
Buy Volume
n/a
n/a
Sell Volume
44Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 10 June 2025
Declarations21 total
100,000 shares@ US$0.700811.6% of flowCommon StockSEC:0001842952-25-000064:0
Canonical exit: 7 Sept 2025 (T+90)
20,000 shares@ US$0.57636.2% of flowCommon StockSEC:0001842952-25-000062:0
Canonical exit: 4 Sept 2025 (T+90)
40,010 shares@ US$0.63733.6% of flowCommon StockSEC:0001842952-25-000060:0
Canonical exit: 4 Sept 2025 (T+90)
5,823 shares@ US$0.84150.5% of flowCommon StockSEC:0001842952-23-000030:0
Canonical exit: 22 May 2023 (T+90)
5,606 shares@ US$0.87420.5% of flowCommon StockSEC:0001842952-23-000020:0
Canonical exit: 14 May 2023 (T+90)
5,040 shares@ US$0.97230.5% of flowCommon StockSEC:0001842952-23-000017:0
Canonical exit: 7 May 2023 (T+90)
7,027 shares@ US$0.69740.5% of flowCommon StockSEC:0001842952-23-000012:0
Canonical exit: 30 Apr 2023 (T+90)
6,839 shares@ US$0.71660.5% of flowCommon StockSEC:0001842952-23-000008:0
Canonical exit: 23 Apr 2023 (T+90)
6,783 shares@ US$0.73640.5% of flowCommon StockSEC:0001842952-23-000006:0
Canonical exit: 17 Apr 2023 (T+90)
20,000 shares@ US$0.73981.6% of flowCommon StockSEC:0001842952-22-000112:0
Canonical exit: 16 Mar 2023 (T+90)
25,000 shares@ US$0.7439.6% of flowCommon StockSEC:0001842952-22-000114:0
Canonical exit: 16 Mar 2023 (T+90)
6,000 shares@ US$0.849115.8% of flowCommon StockSEC:0001842952-22-000110:0
Canonical exit: 9 Mar 2023 (T+90)
13,000 shares@ US$1.85112.7% of flowCommon StockSEC:0001842952-22-000081:0
Canonical exit: 17 Nov 2022 (T+90)
15,000 shares@ US$1.8060.4% of flowCommon StockSEC:0001842952-22-000079:0
Canonical exit: 15 Nov 2022 (T+90)
10,000 shares@ US$1.95100.0% of flowCommon StockSEC:0001842952-22-000077:0
Canonical exit: 14 Nov 2022 (T+90)
13,000 shares@ US$3.21920.019% mcap4.6% of flowCommon StockSEC:0001842952-21-000029:0
Canonical exit: 16 Mar 2022 (T+90)
52,680 shares@ US$7.140.16% mcap40.1% of flowCommon StockSEC:0001842952-21-000027:0
26,587 sharesCommon StockSEC:0001842952-21-000025:0
10,000 shares@ US$5.008.1% of flowCommon StockSEC:0001179110-21-009609:0
Canonical exit: 20 Jan 2022 (T+90)
3,000 shares@ US$5.0046.4% of flowCommon StockSEC:0001179110-21-009610:0
Canonical exit: 20 Jan 2022 (T+90)
26,587 sharesCommon StockSEC:0001179110-21-009608:0
21 of 21 declarations
关于 Context Therapeutics Inc.
Context Therapeutics Inc.（股票代码：CNTX）是一家在美国纳斯达克上市的美国生物制药公司。对于欧洲投资者而言，它符合早期肿瘤生物技术公司的特征：高度研究密集型、资本密集型，并由临床里程碑而非近期商业收入驱动。公司总部位于宾夕法尼亚州费城，这里仍然是其运营基地以及公共沟通和开发工作的中心。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0001842952/000184295225000044/cntx10-kdec312024.pdf?utm_source=openai)) Context 成立于 2015 年 4 月，当时名为 Context Therapeutics LLC，后来发展成为一家上市公司。其早期战略侧重于激素驱动的女性癌症，但随着时间的推移，公司转向了针对实体瘤的下一代 T 细胞接合双特异性抗体。这种战略重新定位很重要：它使 Context 从一个更窄的女性肿瘤故事转变为一个更广泛的免疫肿瘤平台，同时仍然保留了高度专业化的开发模式。2021 年在纳斯达克上市是其重要的融资和可见性事件，有助于支持其向临床阶段公司的转型。（[ir.contexttherapeutics.com](https://ir.contexttherapeutics.com/static-files/2183d3ae-2f63-4ab2-ad2e-90d438b33aa4?utm_source=openai)) 目前，其产品线以三个主要项目为核心。CTIM-76 是一种 CLDN6 x CD3 双特异性抗体；CT-95 是一种靶向间皮素、亲和力增强的 MSLN x CD3 双特异性抗体；CT-202 是一种双 pH 依赖性 Nectin-4 x CD3 双特异性抗体。这些项目旨在利用 T 细胞活性对抗实体瘤，同时力求比早期 T 细胞接合剂具有更好的肿瘤选择性和更易于管理的安全性。在竞争方面，Context 是一家专注的专业公司，而非多元化的制药公司，在一个拥挤的领域中竞争，其中包括大型制药公司和众多追求类似机制的生物技术同行。（[contexttherapeutics.com](https://www.contexttherapeutics.com/?utm_source=openai)) 公司近期的新闻流主要由临床进展驱动。2025 年，Context 报告了 CTIM-76 和 CT-95 正在进行的 1 期剂量递增研究，在主要科学会议上展示了临床前和转化数据，并重申 CT-202 预计将在 2026 年中期推进 IND 申请。这些是投资者密切关注的更新，因为它们定义了公司的下一个价值拐点、监管轨迹和资金需求。（[ir.contexttherapeutics.com](https://ir.contexttherapeutics.com/news-releases/news-release-details/context-therapeutics-reports-second-quarter-2025-operating-and?utm_source=openai)) 从投资者的角度来看，Context Therapeutics 是一个典型的纳斯达克上市临床肿瘤故事：如果早期数据继续支持该平台，则可能带来高收益，但伴随着重大的执行、安全和融资风险。公司目前的定位最适合寻求在美国免疫肿瘤创新领域获得敞口的投资者，其产品线集中于难以治疗的实体瘤，管理层叙述以严谨的临床进展为中心。（[ir.contexttherapeutics.com](https://ir.contexttherapeutics.com/news-releases/news-release-details/context-therapeutics-reports-third-quarter-2025-operating-and?utm_source=openai))
